Specifically regarding the potential relevance of MET/PI3K combinations, in the context of a retrospective review of over 2000 patients, Maryam et al. [50] reported frequent MET-PI3K co-mutations in colorectal adenocarcinoma, thyroid carcinoma, breast adenocarcinoma, and HNC. This evidence concerns the gene MET and thyroid gland carcinoma.